No Detail Found!

Adverse Event Profile in Advance Hepatocellular Carcinoma treated with Sorafenib Presenting to CMH Rawalpindi

Author(s)
Masaba Masood Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Muhammad Nadeem Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Aamira Ali Department of Medical Oncology, POF Hospital Wah Cantt, Pakistan,
Tahir Manzoor Lone Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Amjad Khan Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Assam Ahmad Department of Medical Oncology, THQ Hospital, Baffa, Mansehra Pakistan
Abstract
Objective: To look for adverse event profiles in advance of hepatocellular carcinoma treated with Sorafenib presenting to CMH Rawalpindi and study associated socio-demographic factors Study Design: Comparative cross-sectional study Place and Duration of Study: Oncology Department, Combined Military Hospital, Rawalpindi Pakistan, from Dec 2020 to Nov 2021. Methodology: Three hundred patients with diagnosed hepatocellular carcinoma in advanced stage taking Sorafenib chemotherapy for more than three months and less than one year were included in the study. Each patient was assessed for relevant adverse effects in the follow-up outpatient visits by a consultant oncologist. Results: Out of 300 cancer patients using Sorafenib for more than three months and less than one year, 212(70.7%) patients had at least one or more adverse effects, while 88(29.3%) did not experience any adverse effects. Diarrhoea 120(40%) was the most common adverse effect, followed by rash/desquamation 110(36.7%). Advancing age was statistically significantly associated (p-value-0.001) with adverse effects among the target population. Conclusion: A significant number of patients suffering from hepatocellular carcinoma using Sorafenib had mild to moderate adverse effects. Physicians should keep an eye on patients with advancing age for adverse effects of this medication.
Publication Details
Page(s) 1071-1074
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 73, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
hepatocellular carcinoma, Adverse effects, Sorafenib
0

Citations

0

Downloads

66

Views